Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.11-12

Sonoma Pharmaceuticals (NASDAQ:SNOA) Second Quarter 2025 ResultsKey Financial Results Revenue: US$3.58m (up 31% from 2Q 2024). Net loss: US$610.0k (loss narrowed by 59% from 2Q 2024). US$0.59 loss per...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483861058?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2024-11-12 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483861058","market":"us","top_or_hot":-1,"title":"Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag","media":"Simply Wall St.","content":"<div>\n<p>Sonoma Pharmaceuticals (NASDAQ:SNOA) Second Quarter 2025 ResultsKey Financial Results Revenue: US$3.58m (up 31% from 2Q 2024). Net loss: US$610.0k (loss narrowed by 59% from 2Q 2024). US$0.59 loss per...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-snoa/sonoma-pharmaceuticals/news/sonoma-pharmaceuticals-second-quarter-2025-earnings-eps-beat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-snoa/sonoma-pharmaceuticals/news/sonoma-pharmaceuticals-second-quarter-2025-earnings-eps-beat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sonoma Pharmaceuticals (NASDAQ:SNOA) Second Quarter 2025 ResultsKey Financial Results Revenue: US$3.58m (up 31% from 2Q 2024). Net loss: US$610.0k (loss narrowed by 59% from 2Q 2024). US$0.59 loss per...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-snoa/sonoma-pharmaceuticals/news/sonoma-pharmaceuticals-second-quarter-2025-earnings-eps-beat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNOA","symbol_name":"Sonoma Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-snoa/sonoma-pharmaceuticals/news/sonoma-pharmaceuticals-second-quarter-2025-earnings-eps-beat","article_id":"2483861058","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483861058","pubTimestamp":1731415268,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Second Quarter 2025 Results Key Financial Results Revenue: US$3.58m (up 31% from...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SNOA":"Sonoma Pharmaceuticals, Inc."},"translate_title":"索诺玛制药2025年第二季度收益：每股收益超出预期，收入滞后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNOA":0.9},"content_text":"Sonoma Pharmaceuticals (NASDAQ:SNOA) Second Quarter 2025 ResultsKey Financial Results Revenue: US$3.58m (up 31% from 2Q 2024). Net loss: US$610.0k (loss narrowed by 59% from 2Q 2024). US$0.59 loss per share (improved from US$5.75 loss in 2Q 2024).  NasdaqCM:SNOA Earnings and Revenue Growth November 12th 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period Sonoma Pharmaceuticals EPS Beats Expectations, Revenues Fall Short  Revenue missed analyst estimates by 8.3%.  Earnings per share (EPS) exceeded analyst estimates by 34%.      Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.    Performance of the American Pharmaceuticals industry.  The company's shares are up 13% from a week ago.   Risk Analysis We don't want to rain on the parade too much, but we did also find 4 warning signs for Sonoma Pharmaceuticals (3 are potentially serious!) that you need to be mindful of. New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483861058"}